1 – 10 of 15
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Disease Phenotypes and Prediction of Outcome in ANCA-associated vasculitis
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
- 2023
-
Mark
Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations
(
- Contribution to journal › Scientific review
-
Mark
Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis : A Multinational Retrospective Study
(
- Contribution to journal › Article
-
Mark
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2022
-
Mark
Autoimmune disease – phenotypic alterations of peripheral immune cells and clinical correlates
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Severe infections in patients with ANCA-associated vasculitis treated with rituximab
(
- Contribution to journal › Article
- 2021
-
Mark
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis : A multinational study
(
- Contribution to journal › Article
- 2017
-
Mark
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
-
Mark
Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article